NVS

Novartis AG Form 6-K Summary: Third Quarter 2005 Results

Business Context and Reporting Period

This Form 6-K, dated October 19, 2005, reports the unaudited financial results for Novartis AG for the third quarter and the first nine months ended September 30, 2005. The reporting period reflects the adoption of new IFRS accounting standards effective January 1, 2005. Comparisons to the prior year are presented on a pro forma basis to ensure consistency. The period includes the consolidation of Hexal AG (from June 6) and Eon Labs (from July 20) into the Sandoz division, and the North American OTC business of Bristol-Myers Squibb into Consumer Health (from September 1).

Key Financial Metrics

Cash Flow (YTD 2005): Cash flow from operating activities was USD 5.8 billion. Free cash flow (excluding acquisitions) was USD 3.1 billion.

Material Changes vs. Prior Period

• Revenue Growth: Group net sales rose 19% in Q3 and 14% YTD (USD). Growth was driven by strong underlying performance in Pharmaceuticals (+10% Q3, +11% YTD) and significant acquisition impacts in Sandoz (+106% Q3, +43% YTD).
• Profitability: Operating income increased 17% in Q3 and 13% YTD. Pharmaceuticals operating margin expanded to 33.0% in Q3 (from 30.2%) due to productivity gains. Sandoz operating income was impacted by acquisition-related integration costs and purchase accounting, though underlying performance improved.
• Acquisitions: The consolidation of Hexal and Eon Labs added approximately USD 690 million to Sandoz sales in Q3. The BMS OTC acquisition added 0.5 percentage points to Consumer Health sales growth.
• Liquidity: Net liquidity decreased by USD 6.0 billion to USD 1.0 billion at September 30, 2005, primarily due to USD 8.6 billion in cash outlays for the Hexal, Eon Labs, and BMS OTC acquisitions.

Guidance, Outlook, and Risks

Outlook: Management reaffirmed confidence in achieving full-year 2005 objectives for high-single-digit net sales growth (in local currencies) and record operating and net income levels on a comparable basis to 2004. This outlook excludes the impact of the Hexal and Eon Labs acquisitions.

Acquisition Impact Update: Novartis revised its full-year expectations for the Hexal and Eon Labs acquisitions. The estimated sales contribution is now expected to exceed USD 1.3 billion. The net negative impact on operating income is revised to between USD 75 million and USD 150 million (down from an earlier estimate of USD 150-250 million), and the negative impact on net income is revised to USD 175-250 million.

Pipeline Highlights: Positive Phase III data was reported for LAF237 (diabetes) and SPP100 (hypertension). FTY720 (multiple sclerosis) is on track for Phase III trials by year-end. Aclasta (Paget's disease) showed superior efficacy in a Phase III study.

Risks and Contingencies:

• Impairment: A USD 66 million impairment was recorded for marketing rights related to NKS104 (a statin). Further development is being assessed, with potential for additional impairments.
• Legal: Ongoing litigation includes Canadian importation cases, Chiron/Fluvirin disputes, and product liability suits regarding Fen-Phen and PPA. Novartis believes defenses are substantial but outcomes remain uncertain.
• Regulatory: Elidel sales declined following an FDA health advisory regarding a theoretical lymphoma risk; labeling discussions are ongoing.

Investor Verification Checklist

• Verify the pro forma adjustments applied to 2004 figures to ensure accurate year-over-year comparisons regarding IFRS adoption.
• Monitor the integration progress and cost realization of Hexal and Eon Labs against the revised full-year guidance.
• Track the regulatory status and sales trajectory of Elidel following the FDA advisory.
• Assess the potential for further impairments related to the NKS104 compound.
• Review the status of the proposed acquisition of remaining Chiron Corporation shares, which was rejected by Chiron's independent directors.